文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌伴肝转移患者接受[177Lu]Lu-PSMA-617治疗的结局

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617.
PubMed 文献 · J Nucl Med · 2024-12-03

单中心真实世界数据库纳入2022年3月至2023年3月在Mayo Clinic Rochester接受[177Lu]Lu-PSMA-617治疗的273例患者,其中43例(15.75%)治疗前PSMA PET/CT显示肝转移。肝转移组PSA较基线下降≥50%的应答率低于无肝转移组(30.23%[13/43] vs 49.77%[106/213],P=0.019),中位随访10个月(四分位距9-13个月)时中位总生存有显著差异(8.35个月 vs 未达到,P<0.001),多因素分析显示肝转移与更短生存独立相关(HR 4.06,P<0.001)。作者认为肝转移预示LuPSMA治疗结局较差,应探索替代和联合方案以最大化肝脏放射性药物治疗的抗肿瘤活性。

要点

  • 肝转移组PSA下降≥50%应答率30.23%(13/43)低于无肝转移组49.77%(106/213),P=0.019。
  • 中位随访10个月时中位OS为肝转移组8.35个月 vs 无肝转移组未达到,P<0.001。
  • 多因素分析显示肝转移与更短生存独立相关(HR 4.06,P<0.001)。

核心结论

  • 作者认为肝转移预示接受LuPSMA治疗的患者结局较差。
  • 作者提出应探索替代和联合方案以最大化肝脏放射性药物治疗的抗肿瘤活性。

研究设计与样本

  • 单机构数据库纳入2022年3月至2023年3月在Mayo Clinic Rochester启动LuPSMA治疗的全部患者,共273例。
  • 按治疗前PSMA PET有无肝转移分为两组,比较PSA应答(χ2检验)和OS(Kaplan-Meier法),并行多因素Cox回归。
  • 对治疗前有83基因面板循环肿瘤DNA结果者评估致病及可能致病性变异,用描述性统计总结并以Fisher精确检验比较两组。

主要发现

  • 全队列273例中43例(15.75%)治疗前PSMA PET/CT显示肝转移。
  • 肝转移组接受中位3个周期(范围1-6),无肝转移组中位5个周期(范围1-6)。
  • PSA较基线下降≥50%的应答率肝转移组30.23%(13/43) vs 无肝转移组49.77%(106/213),P=0.019。
  • 中位随访10个月(四分位距9-13个月)时中位OS肝转移组8.35个月 vs 无肝转移组未达到,P<0.001。
  • 多因素分析中肝转移与更短生存独立相关(HR 4.06,P<0.001)。

关键数值与推荐

  • PSA应答定义为较基线下降≥50%。
  • 肝转移组PSA应答率30.23%(13/43) vs 无肝转移组49.77%(106/213),P=0.019。
  • 中位OS肝转移组8.35个月 vs 无肝转移组未达到,P<0.001。
  • 肝转移与更短生存的多因素HR 4.06,P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is well known that patients with liver metastasis from metastatic castration-resistant prostate cancer have poor or only transient responses to many forms of systemic therapy. Data on outcomes after treatment with [177Lu]Lu-PSMA-617 (LuPSMA) are scarce. The VISION trial reports a hazard ratio for overall survival (OS) in the subgroup of patients with liver metastasis without disclosing the absolute duration of survival. Using real-world clinical data, we examined this important subgroup of patients, describing prostate-specific antigen (PSA) response and OS. Methods: A single-institution database was assembled to include all patients receiving LuPSMA at Mayo Clinic in Rochester, Minnesota, for whom treatment was initiated between March 2022 and March 2023. Baseline clinicopathologic and imaging characteristics were abstracted. Patients were then categorized by presence or absence of liver metastasis on pretreatment prostate-specific membrane antigen (PSMA) PET. PSA response and OS for the 2 groups (liver metastasis vs. no liver metastasis) were compared using χ2 testing and the Kaplan-Meier method, respectively. A multivariate Cox regression analysis was performed, including established prognostic factors. Finally, those with pretreatment circulating tumor DNA as determined in an 83-gene panel were assessed for the presence of pathogenic and likely pathogenic alterations. These findings were summarized using descriptive statistics and compared between the 2 cohorts using the Fisher exact test. Results: The overall cohort consisted of 273 patients, including 43 (15.75%) with liver metastasis on pretreatment PSMA PET/CT. The median number of cycles received was 3 (range, 1-6) for patients with liver metastasis and 5 (range, 1-6) for those without hepatic involvement. The 50% or greater reduction in PSA from baseline response rate was lower for those with liver metastasis than for those without (30.23% [13/43] vs 49.77% [106/213], P = 0.019). At a median follow-up of 10 mo (interquartile range, 9-13 mo), there was a significant difference in median OS (8.35 mo vs. not reached, P < 0.001). On multivariate analysis, the presence of liver metastasis was independently associated with shorter survival (hazard ratio, 4.06; P < 0.001). Conclusion: Our data suggest that the presence of liver metastasis predicts poorer outcomes in patients receiving LuPSMA treatment. Alternative and combination approaches should be explored to maximize the antitumor activity of radiopharmaceutical therapy in the liver.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Muniz M, Sartor O, Orme JJ, et al. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617. J Nucl Med. 2024. PMID: 39477495. doi:10.2967/jnumed.124.268277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。